News
Relief Therapeutics to Participate in January Investor Meetings
Relief Therapeutics to Participate in January Investor Meetings
Relief Therapeutics Announces Issuance of Shares from Authorized Capital
Relief Therapeutics Announces Issuance of Shares from Authorized Capital
EQS-News: BB BIOTECH AG: Molecular strike force for the immune system
EQS-News: BB BIOTECH AG: Molecular strike force for the immune system
Relief Therapeutics Announces Executive Leadership Team Changes
Relief Therapeutics Announces Executive Leadership Team Changes
Sonova completes acquisition of the HYSOUND Group, expanding direct consumer access in China
Sonova completes acquisition of the HYSOUND Group, expanding direct consumer access in China
Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221127005020/en/
CSL Vifor and Fresenius Kabi today announced that
Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH
Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab
GeNeuro (Paris:GNRO)(Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such
GeNeuro meldet erste Patientenrekrutierungen in allen fünf schweizerischen Zentren für die erste klinische Studie mit Temelimab zur personalisierten Medizin gegen Long COVID
GeNeuro (Euronext Paris: CH0308403085 - GNRO), ein biopharmazeutisches Unternehmen, das sich darauf konzentriert, die kausalen Faktoren zu stoppen, die das Fortschreiten von neurodegenerativen und
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
First half results 2022/23: Growth in all regions and further progress on strategic initiatives
First half results 2022/23:
Growth in all regions and further progress on strategic initiatives
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
Evolva receives approval for Veri-teTM Resveratrol for animal health in Brazil
Evolva receives approval for Veri-teTM Resveratrol for animal health in Brazil
Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay of pending litigation to provide additional time for the parties to finalize their litigation settlement
Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay of pending litigation to provide additional time for the parties to finalize their litigation settlement
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)
Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules
Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules
Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine
Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine
Kuros reports 73% increase in MagnetOs sales in first nine months of 2022
Kuros reports 73% increase in MagnetOs sales in first nine months of 2022
RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. extend their stay of pending litigation to provide additional time for the parties to finalize their settlement
RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. extend their stay of pending litigation to provide additional time for the parties to finalize their settlement
Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission
Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission